These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15280442)

  • 1. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2.
    Bellocq C; Wilders R; Schott JJ; Louérat-Oriou B; Boisseau P; Le Marec H; Escande D; Baró I
    Mol Pharmacol; 2004 Nov; 66(5):1093-102. PubMed ID: 15280442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6.
    Lu Y; Mahaut-Smith MP; Huang CL; Vandenberg JI
    J Physiol; 2003 Aug; 551(Pt 1):253-62. PubMed ID: 12923204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentamidine-induced long QT syndrome and block of hERG trafficking.
    Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
    J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency.
    Paulussen AD; Raes A; Jongbloed RJ; Gilissen RA; Wilde AA; Snyders DJ; Smeets HJ; Aerssens J
    Cardiovasc Res; 2005 Aug; 67(3):467-75. PubMed ID: 15958262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
    Dustan Sarazan R; Crumb WJ; Beasley CM; Emmick JT; Ferguson KM; Strnat CA; Sausen PJ
    Eur J Pharmacol; 2004 Oct; 502(3):163-7. PubMed ID: 15476742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations.
    Lupoglazoff JM; Denjoy I; Villain E; Fressart V; Simon F; Bozio A; Berthet M; Benammar N; Hainque B; Guicheney P
    J Am Coll Cardiol; 2004 Mar; 43(5):826-30. PubMed ID: 14998624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
    Choi SY; Koh YS; Jo SH
    J Pharmacol Exp Ther; 2005 May; 313(2):888-95. PubMed ID: 15722405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR
    Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants of high-affinity drug binding to HERG channels.
    Mitcheson JS; Perry MD
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel KCNE3 mutation reduces repolarizing potassium current and associated with long QT syndrome.
    Ohno S; Toyoda F; Zankov DP; Yoshida H; Makiyama T; Tsuji K; Honda T; Obayashi K; Ueyama H; Shimizu W; Miyamoto Y; Kamakura S; Matsuura H; Kita T; Horie M
    Hum Mutat; 2009 Apr; 30(4):557-63. PubMed ID: 19306396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA; Su Z; Martin RL; Cox BF
    Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of human ERG K+ channels in the mouse heart exerts anti-arrhythmic activity.
    Royer A; Demolombe S; El Harchi A; Le Quang K; Piron J; Toumaniantz G; Mazurais D; Bellocq C; Lande G; Terrenoire C; Motoike HK; Chevallier JC; Loussouarn G; Clancy CE; Escande D; Charpentier F
    Cardiovasc Res; 2005 Jan; 65(1):128-37. PubMed ID: 15621040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine.
    Kim MD; Eun SY; Jo SH
    Eur J Pharmacol; 2006 Aug; 544(1-3):82-90. PubMed ID: 16860311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clobutinol delays ventricular repolarization in the guinea pig heart: comparison with cardiac effects of HERG K+ channel inhibitor E-4031.
    Takahara A; Sasaki R; Nakamura M; Sendo A; Sakurai Y; Namekata I; Tanaka H
    J Cardiovasc Pharmacol; 2009 Dec; 54(6):552-9. PubMed ID: 19770670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
    Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
    Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of sevoflurane and propofol on QT interval and heterologously expressed human ether-a-go-go related gene currents in Xenopus oocytes.
    Yamada M; Hatakeyama N; Malykhina AP; Yamazaki M; Momose Y; Akbarali HI
    Anesth Analg; 2006 Jan; 102(1):98-103. PubMed ID: 16368812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.